nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—PRKCE—liver cancer	0.404	1	CbGaD
Ruxolitinib—MKNK2—Sorafenib—liver cancer	0.114	0.265	CbGbCtD
Ruxolitinib—TAOK2—Sorafenib—liver cancer	0.114	0.265	CbGbCtD
Ruxolitinib—MAP3K7—Sorafenib—liver cancer	0.0908	0.21	CbGbCtD
Ruxolitinib—RET—Sorafenib—liver cancer	0.0656	0.152	CbGbCtD
Ruxolitinib—MAP3K19—Sorafenib—liver cancer	0.0436	0.101	CbGbCtD
Ruxolitinib—Blood pressure systolic increased—Sorafenib—liver cancer	0.00488	0.24	CcSEcCtD
Ruxolitinib—RPS6KA6—embryo—liver cancer	0.00189	0.0794	CbGeAlD
Ruxolitinib—CYP3A4—Sorafenib—liver cancer	0.00186	0.00431	CbGbCtD
Ruxolitinib—PLK3—embryo—liver cancer	0.00158	0.0663	CbGeAlD
Ruxolitinib—JAK1—embryo—liver cancer	0.00121	0.0508	CbGeAlD
Ruxolitinib—DCLK1—embryo—liver cancer	0.00121	0.0508	CbGeAlD
Ruxolitinib—CYP3A4—Doxorubicin—liver cancer	0.00113	0.00262	CbGbCtD
Ruxolitinib—ROCK1—embryo—liver cancer	0.00104	0.0438	CbGeAlD
Ruxolitinib—PRKG2—liver—liver cancer	0.000975	0.0409	CbGeAlD
Ruxolitinib—PRKCE—liver—liver cancer	0.00091	0.0382	CbGeAlD
Ruxolitinib—PLK1—liver—liver cancer	0.000875	0.0367	CbGeAlD
Ruxolitinib—RPS6KA6—liver—liver cancer	0.000875	0.0367	CbGeAlD
Ruxolitinib—RET—embryo—liver cancer	0.000771	0.0324	CbGeAlD
Ruxolitinib—PLK3—liver—liver cancer	0.00073	0.0306	CbGeAlD
Ruxolitinib—JAK2—embryo—liver cancer	0.000728	0.0306	CbGeAlD
Ruxolitinib—CAMK1—liver—liver cancer	0.000683	0.0287	CbGeAlD
Ruxolitinib—TAOK2—liver—liver cancer	0.000613	0.0257	CbGeAlD
Ruxolitinib—JAK1—liver—liver cancer	0.00056	0.0235	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—liver cancer	0.000558	0.0275	CcSEcCtD
Ruxolitinib—CAMK1D—liver—liver cancer	0.000547	0.0229	CbGeAlD
Ruxolitinib—PHKG2—liver—liver cancer	0.000543	0.0228	CbGeAlD
Ruxolitinib—STK16—liver—liver cancer	0.000526	0.0221	CbGeAlD
Ruxolitinib—HIPK2—liver—liver cancer	0.000523	0.022	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—liver cancer	0.000516	0.0254	CcSEcCtD
Ruxolitinib—DAPK3—liver—liver cancer	0.000502	0.0211	CbGeAlD
Ruxolitinib—CLK2—liver—liver cancer	0.000498	0.0209	CbGeAlD
Ruxolitinib—ROCK1—liver—liver cancer	0.000482	0.0202	CbGeAlD
Ruxolitinib—DYRK1A—liver—liver cancer	0.00047	0.0197	CbGeAlD
Ruxolitinib—BMPR2—liver—liver cancer	0.000468	0.0197	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000453	0.0223	CcSEcCtD
Ruxolitinib—NUAK2—liver—liver cancer	0.000448	0.0188	CbGeAlD
Ruxolitinib—BMP2K—liver—liver cancer	0.000419	0.0176	CbGeAlD
Ruxolitinib—CAMK2G—liver—liver cancer	0.000419	0.0176	CbGeAlD
Ruxolitinib—LRRK2—liver—liver cancer	0.000415	0.0174	CbGeAlD
Ruxolitinib—Neutropenia—Sorafenib—liver cancer	0.000415	0.0204	CcSEcCtD
Ruxolitinib—Weight decreased—Sorafenib—liver cancer	0.000402	0.0198	CcSEcCtD
Ruxolitinib—Infestation NOS—Sorafenib—liver cancer	0.000396	0.0195	CcSEcCtD
Ruxolitinib—Infestation—Sorafenib—liver cancer	0.000396	0.0195	CcSEcCtD
Ruxolitinib—MAP3K2—liver—liver cancer	0.000381	0.016	CbGeAlD
Ruxolitinib—MAP3K7—liver—liver cancer	0.000377	0.0158	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Sorafenib—liver cancer	0.000375	0.0184	CcSEcCtD
Ruxolitinib—Epistaxis—Sorafenib—liver cancer	0.000374	0.0184	CcSEcCtD
Ruxolitinib—TYK2—liver—liver cancer	0.00037	0.0155	CbGeAlD
Ruxolitinib—IRAK1—liver—liver cancer	0.000365	0.0153	CbGeAlD
Ruxolitinib—MKNK2—liver—liver cancer	0.000365	0.0153	CbGeAlD
Ruxolitinib—Haemoglobin—Sorafenib—liver cancer	0.000357	0.0176	CcSEcCtD
Ruxolitinib—Haemorrhage—Sorafenib—liver cancer	0.000356	0.0175	CcSEcCtD
Ruxolitinib—Herpes zoster—Epirubicin—liver cancer	0.000347	0.0171	CcSEcCtD
Ruxolitinib—JAK2—liver—liver cancer	0.000337	0.0141	CbGeAlD
Ruxolitinib—MAP3K3—liver—liver cancer	0.000325	0.0136	CbGeAlD
Ruxolitinib—Herpes zoster—Doxorubicin—liver cancer	0.000321	0.0158	CcSEcCtD
Ruxolitinib—Malnutrition—Sorafenib—liver cancer	0.000309	0.0152	CcSEcCtD
Ruxolitinib—TAOK3—liver—liver cancer	0.000296	0.0124	CbGeAlD
Ruxolitinib—Anaemia—Sorafenib—liver cancer	0.000286	0.0141	CcSEcCtD
Ruxolitinib—Bone pain—Epirubicin—liver cancer	0.000273	0.0134	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000262	0.0129	CcSEcCtD
Ruxolitinib—Bone pain—Doxorubicin—liver cancer	0.000253	0.0124	CcSEcCtD
Ruxolitinib—Infection—Sorafenib—liver cancer	0.000251	0.0124	CcSEcCtD
Ruxolitinib—Nervous system disorder—Sorafenib—liver cancer	0.000248	0.0122	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Sorafenib—liver cancer	0.000247	0.0122	CcSEcCtD
Ruxolitinib—Skin disorder—Sorafenib—liver cancer	0.000245	0.0121	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000218	0.0107	CcSEcCtD
Ruxolitinib—Fatigue—Sorafenib—liver cancer	0.000218	0.0107	CcSEcCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—liver cancer	0.000212	0.081	CbGdCrCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—liver cancer	0.000212	0.081	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—liver cancer	0.000212	0.081	CbGdCrCtD
Ruxolitinib—Body temperature increased—Sorafenib—liver cancer	0.0002	0.00983	CcSEcCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—liver cancer	0.000196	0.0749	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—liver cancer	0.000196	0.0749	CbGdCrCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—liver cancer	0.000196	0.0749	CbGdCrCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00019	0.00935	CcSEcCtD
Ruxolitinib—Asthenia—Sorafenib—liver cancer	0.000181	0.00892	CcSEcCtD
Ruxolitinib—Pruritus—Sorafenib—liver cancer	0.000179	0.0088	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000176	0.00865	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000168	0.00825	CcSEcCtD
Ruxolitinib—Dizziness—Sorafenib—liver cancer	0.000167	0.00822	CcSEcCtD
Ruxolitinib—Headache—Sorafenib—liver cancer	0.000158	0.00779	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—liver cancer	0.000156	0.00767	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000155	0.00763	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—liver cancer	0.000153	0.00756	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—liver cancer	0.000149	0.00735	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—liver cancer	0.000149	0.00731	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—liver cancer	0.000146	0.0072	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—liver cancer	0.000146	0.0072	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—liver cancer	0.000145	0.0553	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—liver cancer	0.000145	0.0553	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—liver cancer	0.000145	0.0553	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—liver cancer	0.000145	0.0553	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—liver cancer	0.000145	0.0553	CbGdCrCtD
Ruxolitinib—Pancytopenia—Doxorubicin—liver cancer	0.000144	0.0071	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—liver cancer	0.000142	0.007	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—liver cancer	0.000142	0.00699	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—liver cancer	0.00014	0.00687	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—liver cancer	0.000138	0.00681	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—liver cancer	0.000138	0.0068	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—liver cancer	0.000138	0.0068	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—liver cancer	0.000137	0.00676	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—liver cancer	0.000135	0.00667	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—liver cancer	0.000135	0.00667	CcSEcCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—liver cancer	0.000134	0.0512	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—liver cancer	0.000134	0.0512	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—liver cancer	0.000134	0.0512	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—liver cancer	0.000134	0.0512	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—liver cancer	0.000134	0.0512	CbGdCrCtD
Ruxolitinib—Haemoglobin—Epirubicin—liver cancer	0.000132	0.0065	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—liver cancer	0.000132	0.00648	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—liver cancer	0.000131	0.00647	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—liver cancer	0.000129	0.00636	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—liver cancer	0.000128	0.0063	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—liver cancer	0.000128	0.00629	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—liver cancer	0.000122	0.00601	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—liver cancer	0.000122	0.00598	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—liver cancer	0.000114	0.00563	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—liver cancer	0.000113	0.00555	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—liver cancer	0.000106	0.00521	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—liver cancer	0.000106	0.0052	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—liver cancer	0.000104	0.00513	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—liver cancer	9.78e-05	0.00481	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	9.67e-05	0.00476	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—liver cancer	9.27e-05	0.00456	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—liver cancer	9.15e-05	0.00451	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—liver cancer	9.14e-05	0.0045	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—liver cancer	9.07e-05	0.00446	CcSEcCtD
Ruxolitinib—CYP3A4—liver—liver cancer	8.99e-05	0.00378	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	8.95e-05	0.0044	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—liver cancer	8.58e-05	0.00422	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—liver cancer	8.47e-05	0.00417	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—liver cancer	8.46e-05	0.00416	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—liver cancer	8.39e-05	0.00413	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—liver cancer	8.06e-05	0.00397	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—liver cancer	8.05e-05	0.00396	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—liver cancer	7.46e-05	0.00367	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—liver cancer	7.45e-05	0.00367	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—liver cancer	7.38e-05	0.00363	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—liver cancer	6.83e-05	0.00336	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—liver cancer	6.7e-05	0.0033	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—liver cancer	6.6e-05	0.00325	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—liver cancer	6.2e-05	0.00305	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—liver cancer	6.17e-05	0.00304	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—liver cancer	6.11e-05	0.00301	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—liver cancer	5.85e-05	0.00288	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—liver cancer	5.71e-05	0.00281	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—liver cancer	5.41e-05	0.00266	CcSEcCtD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—liver cancer	1.51e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—liver cancer	1.51e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—liver cancer	1.5e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1A—liver cancer	1.5e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CB—liver cancer	1.5e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MTOR—liver cancer	1.5e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—liver cancer	1.49e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—liver cancer	1.48e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—liver cancer	1.48e-06	1.26e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1A—liver cancer	1.48e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CD—liver cancer	1.47e-06	1.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK8—liver cancer	1.46e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—liver cancer	1.46e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—liver cancer	1.45e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CPT1B—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLUL—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—liver cancer	1.45e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—liver cancer	1.44e-06	1.23e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK8—liver cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—liver cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—liver cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—liver cancer	1.42e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CD—liver cancer	1.42e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—RAF1—liver cancer	1.42e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—liver cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—liver cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—liver cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1B—liver cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—liver cancer	1.39e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NR1H4—liver cancer	1.39e-06	1.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—liver cancer	1.39e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTOR—liver cancer	1.38e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CB—liver cancer	1.38e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—liver cancer	1.38e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—liver cancer	1.37e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA3—liver cancer	1.37e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK14—liver cancer	1.36e-06	1.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—liver cancer	1.35e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—liver cancer	1.35e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RAF1—liver cancer	1.35e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—liver cancer	1.35e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—liver cancer	1.34e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—liver cancer	1.34e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—liver cancer	1.34e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—liver cancer	1.34e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—liver cancer	1.34e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—liver cancer	1.33e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—liver cancer	1.33e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—liver cancer	1.33e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—F2—liver cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—liver cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—liver cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—liver cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—liver cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—liver cancer	1.31e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—liver cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RAF1—liver cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—liver cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—liver cancer	1.3e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—liver cancer	1.3e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—liver cancer	1.29e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—liver cancer	1.28e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—liver cancer	1.28e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—liver cancer	1.28e-06	1.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—liver cancer	1.27e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RAF1—liver cancer	1.27e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—liver cancer	1.27e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—liver cancer	1.26e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—liver cancer	1.26e-06	1.08e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA4—liver cancer	1.25e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—liver cancer	1.24e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—liver cancer	1.24e-06	1.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—liver cancer	1.24e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—liver cancer	1.24e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—liver cancer	1.24e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—liver cancer	1.24e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—liver cancer	1.23e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—liver cancer	1.23e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—liver cancer	1.23e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—liver cancer	1.22e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA2—liver cancer	1.22e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—liver cancer	1.22e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—liver cancer	1.22e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—liver cancer	1.21e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—liver cancer	1.21e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—liver cancer	1.21e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—liver cancer	1.21e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—liver cancer	1.2e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—liver cancer	1.2e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—liver cancer	1.19e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—liver cancer	1.19e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—liver cancer	1.19e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—liver cancer	1.18e-06	1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA1—liver cancer	1.18e-06	1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—liver cancer	1.18e-06	1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—liver cancer	1.18e-06	1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—liver cancer	1.17e-06	9.98e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—liver cancer	1.17e-06	9.94e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—liver cancer	1.17e-06	9.93e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—liver cancer	1.17e-06	9.93e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAT2—liver cancer	1.17e-06	9.91e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—liver cancer	1.16e-06	9.89e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—liver cancer	1.16e-06	9.85e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—liver cancer	1.15e-06	9.77e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—liver cancer	1.15e-06	9.77e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—liver cancer	1.14e-06	9.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—liver cancer	1.14e-06	9.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—liver cancer	1.14e-06	9.71e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—liver cancer	1.14e-06	9.7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—liver cancer	1.14e-06	9.7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—liver cancer	1.14e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—liver cancer	1.14e-06	9.65e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—liver cancer	1.13e-06	9.64e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—liver cancer	1.13e-06	9.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOB—liver cancer	1.12e-06	9.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—liver cancer	1.12e-06	9.48e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—liver cancer	1.11e-06	9.47e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—liver cancer	1.11e-06	9.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—liver cancer	1.11e-06	9.45e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—liver cancer	1.11e-06	9.45e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—liver cancer	1.11e-06	9.44e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—liver cancer	1.11e-06	9.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—liver cancer	1.11e-06	9.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—liver cancer	1.1e-06	9.36e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—liver cancer	1.1e-06	9.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—liver cancer	1.1e-06	9.35e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—liver cancer	1.1e-06	9.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—liver cancer	1.09e-06	9.25e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—liver cancer	1.09e-06	9.24e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—liver cancer	1.08e-06	9.2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—liver cancer	1.08e-06	9.19e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—liver cancer	1.08e-06	9.16e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—liver cancer	1.08e-06	9.16e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—liver cancer	1.07e-06	9.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—liver cancer	1.07e-06	9.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—liver cancer	1.07e-06	9.08e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CRABP1—liver cancer	1.07e-06	9.06e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—liver cancer	1.06e-06	8.98e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—liver cancer	1.05e-06	8.91e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—liver cancer	1.04e-06	8.83e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—liver cancer	1.04e-06	8.8e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—liver cancer	1.03e-06	8.76e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—liver cancer	1.03e-06	8.74e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—liver cancer	1.02e-06	8.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—liver cancer	1.02e-06	8.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—liver cancer	1.01e-06	8.62e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—liver cancer	1e-06	8.54e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—liver cancer	1e-06	8.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—liver cancer	1e-06	8.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—liver cancer	9.98e-07	8.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—liver cancer	9.94e-07	8.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—liver cancer	9.94e-07	8.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RAF1—liver cancer	9.92e-07	8.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—liver cancer	9.91e-07	8.43e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—liver cancer	9.88e-07	8.4e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—liver cancer	9.86e-07	8.38e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—liver cancer	9.85e-07	8.37e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—liver cancer	9.77e-07	8.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—liver cancer	9.69e-07	8.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—liver cancer	9.69e-07	8.24e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—liver cancer	9.68e-07	8.23e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—liver cancer	9.61e-07	8.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—liver cancer	9.58e-07	8.15e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—liver cancer	9.55e-07	8.12e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—liver cancer	9.46e-07	8.04e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—liver cancer	9.43e-07	8.02e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—liver cancer	9.35e-07	7.95e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HPGDS—liver cancer	9.32e-07	7.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—liver cancer	9.25e-07	7.87e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—liver cancer	9.19e-07	7.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—liver cancer	9.18e-07	7.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—liver cancer	9.18e-07	7.81e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—liver cancer	9.16e-07	7.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—liver cancer	9.14e-07	7.77e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—liver cancer	9.09e-07	7.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—liver cancer	9.09e-07	7.73e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—liver cancer	8.99e-07	7.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—liver cancer	8.91e-07	7.58e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—liver cancer	8.9e-07	7.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—liver cancer	8.9e-07	7.57e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—liver cancer	8.88e-07	7.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—liver cancer	8.85e-07	7.53e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—liver cancer	8.74e-07	7.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—liver cancer	8.67e-07	7.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—liver cancer	8.66e-07	7.36e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—liver cancer	8.62e-07	7.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—liver cancer	8.59e-07	7.3e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—liver cancer	8.48e-07	7.21e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—liver cancer	8.48e-07	7.21e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—liver cancer	8.45e-07	7.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—liver cancer	8.43e-07	7.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—liver cancer	8.42e-07	7.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—liver cancer	8.39e-07	7.13e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMA4—liver cancer	8.3e-07	7.06e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMD10—liver cancer	8.3e-07	7.06e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—liver cancer	8.23e-07	7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—liver cancer	8.19e-07	6.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—liver cancer	8.17e-07	6.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—liver cancer	8.09e-07	6.88e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT2—liver cancer	8.08e-07	6.87e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—liver cancer	8.03e-07	6.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—liver cancer	7.8e-07	6.64e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—liver cancer	7.79e-07	6.63e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—liver cancer	7.77e-07	6.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2E1—liver cancer	7.6e-07	6.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—liver cancer	7.56e-07	6.43e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—liver cancer	7.56e-07	6.43e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—liver cancer	7.54e-07	6.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—liver cancer	7.49e-07	6.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—liver cancer	7.47e-07	6.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—liver cancer	7.46e-07	6.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—liver cancer	7.43e-07	6.32e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—liver cancer	7.31e-07	6.22e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—liver cancer	7.21e-07	6.13e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—liver cancer	7.11e-07	6.04e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYCS—liver cancer	7.11e-07	6.04e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—liver cancer	6.99e-07	5.95e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT1—liver cancer	6.97e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GGT1—liver cancer	6.97e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—liver cancer	6.96e-07	5.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—liver cancer	6.94e-07	5.9e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—liver cancer	6.9e-07	5.87e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—liver cancer	6.89e-07	5.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—liver cancer	6.69e-07	5.69e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—liver cancer	6.56e-07	5.58e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—liver cancer	6.43e-07	5.47e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—liver cancer	6.37e-07	5.41e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—liver cancer	6.26e-07	5.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—liver cancer	6.18e-07	5.25e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—liver cancer	6.18e-07	5.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—liver cancer	5.91e-07	5.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—liver cancer	5.76e-07	4.89e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—liver cancer	5.71e-07	4.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—liver cancer	5.46e-07	4.65e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A1—liver cancer	5.46e-07	4.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—liver cancer	5.23e-07	4.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—liver cancer	5.09e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARA—liver cancer	4.99e-07	4.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—liver cancer	4.83e-07	4.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—liver cancer	4.27e-07	3.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—liver cancer	4.13e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—liver cancer	3.76e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—liver cancer	3.71e-07	3.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—liver cancer	3.28e-07	2.78e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—liver cancer	2e-07	1.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—liver cancer	1.63e-07	1.39e-06	CbGpPWpGaD
